Xencor, Inc.

NasdaqGM:XNCR Stock Report

Market Cap: US$592.9m

Xencor Valuation

Is XNCR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of XNCR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$47.50
Fair Value
82.5% undervalued intrinsic discount
10
Number of Analysts

Below Fair Value: XNCR ($8.33) is trading below our estimate of fair value ($47.79)

Significantly Below Fair Value: XNCR is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for XNCR?

Key metric: As XNCR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for XNCR. This is calculated by dividing XNCR's market cap by their current revenue.
What is XNCR's PS Ratio?
PS Ratio4.7x
SalesUS$127.23m
Market CapUS$592.85m

Price to Sales Ratio vs Peers

How does XNCR's PS Ratio compare to its peers?

The above table shows the PS ratio for XNCR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.8x
AKBA Akebia Therapeutics
3.6x24.8%US$667.6m
MGTX MeiraGTx Holdings
12.8x31.8%US$431.3m
ZYME Zymeworks
8.4x15.2%US$786.6m
RCUS Arcus Biosciences
6.2x38.4%US$876.7m
XNCR Xencor
4.7x25.0%US$625.6m

Price-To-Sales vs Peers: XNCR is good value based on its Price-To-Sales Ratio (4.7x) compared to the peer average (7.5x).

Price to Sales Ratio vs Industry

How does XNCR's PS Ratio compare vs other companies in the US Biotechs Industry?

156 CompaniesPrice / SalesEstimated GrowthMarket Cap
REGN Regeneron Pharmaceuticals
4x6.3%US$57.87b
BIIB Biogen
1.8x-0.7%US$17.35b
INCY Incyte
2.6x3.2%US$11.56b
BMRN BioMarin Pharmaceutical
3.8x7.1%US$11.47b
XNCR 4.7xIndustry Avg. 7.6xNo. of Companies156PS01632486480+
156 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: XNCR is good value based on its Price-To-Sales Ratio (4.7x) compared to the US Biotechs industry average (8x).

Price to Sales Ratio vs Fair Ratio

What is XNCR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

XNCR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.7x
Fair PS Ratio0.9x

Price-To-Sales vs Fair Ratio: XNCR is expensive based on its Price-To-Sales Ratio (4.7x) compared to the estimated Fair Price-To-Sales Ratio (1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst XNCR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$8.33
US$28.20
+238.5%
32.8%US$40.00US$6.00n/a10
May ’26US$10.86
US$30.30
+179.0%
18.3%US$40.00US$22.00n/a10
Apr ’26US$9.69
US$30.30
+212.7%
18.3%US$40.00US$22.00n/a10
Mar ’26US$15.36
US$30.64
+99.5%
17.6%US$40.00US$22.00n/a11
Feb ’26US$18.28
US$32.91
+80.0%
15.5%US$40.00US$22.00n/a11
Jan ’26US$22.98
US$32.91
+43.2%
15.5%US$40.00US$22.00n/a11
Dec ’25US$25.60
US$31.50
+23.0%
20.2%US$40.00US$20.00n/a10
Nov ’25US$21.26
US$33.09
+55.6%
24.5%US$50.00US$20.00n/a11
Oct ’25US$19.64
US$32.82
+67.1%
24.2%US$50.00US$20.00n/a11
Sep ’25US$17.49
US$32.64
+86.6%
23.9%US$50.00US$21.00n/a11
Aug ’25US$19.90
US$33.58
+68.8%
22.6%US$50.00US$21.00n/a12
Jul ’25US$19.02
US$33.83
+77.9%
21.9%US$50.00US$21.00n/a12
Jun ’25US$23.76
US$35.92
+51.2%
26.5%US$58.00US$22.00n/a12
May ’25US$23.93
US$35.83
+49.7%
26.5%US$58.00US$22.00US$10.8612
Apr ’25US$21.92
US$37.33
+70.3%
29.5%US$58.00US$22.00US$9.6912
Mar ’25US$23.82
US$37.33
+56.7%
29.5%US$58.00US$22.00US$15.3612
Feb ’25US$19.06
US$37.18
+95.1%
23.3%US$56.00US$22.00US$18.2811
Jan ’25US$21.23
US$38.18
+79.8%
26.4%US$59.00US$22.00US$22.9811
Dec ’24US$18.80
US$39.71
+111.2%
26.5%US$59.00US$22.00US$25.6014
Nov ’24US$17.47
US$43.57
+149.4%
20.5%US$59.00US$27.00US$21.2614
Oct ’24US$20.15
US$43.57
+116.2%
20.5%US$59.00US$27.00US$19.6414
Sep ’24US$22.43
US$44.14
+96.8%
19.8%US$59.00US$27.00US$17.4914
Aug ’24US$24.03
US$43.79
+82.2%
20.2%US$59.00US$27.00US$19.9014
Jul ’24US$24.97
US$44.21
+77.1%
19.4%US$59.00US$27.00US$19.0214
Jun ’24US$27.14
US$44.21
+62.9%
19.4%US$59.00US$27.00US$23.7614
May ’24US$27.07
US$45.21
+67.0%
18.5%US$59.00US$27.00US$23.9314
AnalystConsensusTarget
Consensus Narrative from 10 Analysts
US$28.20
Fair Value
70.5% undervalued intrinsic discount
10
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/10 20:36
End of Day Share Price 2025/05/09 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Xencor, Inc. is covered by 21 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Zhiqiang ShuBerenberg
Alec StranahanBofA Global Research